Why uniQure (QURE) Is Down 5.9% After Fresh Huntington’s Gene Therapy Data Update And What’s Next

• uniQure N.V. recently reported additional 36- and 48-month Phase I/II data for its Huntington's disease gene therapy ifezuntirgene inilparvovec, showing continued slowing of disease progression versus matched external controls and supporting its previously submitted accelerated approval BLA.

• The update highlights durable, dose-dependent effects across key clinical measures and a generally manageable safety profile, reinforcing ifezuntirgene inilparvovec's potential as a first-in-class, one-time treatment approach for Huntington's disease.

• We'll now examine how the FDA's willingness to base accelerated approval review on 36-month high-dose data could reshape uniQure's investment narrative.

The latest GPUs need a type of rare earth metal called Terbium and there are only 33 companies in the world exploring or producing it . Find the list for free.

uniQure Investment Narrative Recap

To own uniQure, you have to believe ifezuntirgene inilparvovec can clear U.S. and U.K. regulators and become a meaningful Huntington's disease therapy, despite the company's current losses and dependence on this single asset. The latest 36 and 48 month data strengthen the medical story and appear supportive of the already submitted accelerated approval BLA, but they do not remove the core near term risk that regulators could still push back on an external control based package.

The most directly relevant prior milestone is the September 2, 2026 announcement that uniQure had submitted a BLA to the FDA and an MAA to the U.K. MHRA for ifezuntirgene inilparvovec, requesting priority review. The new, longer term Phase I/II data now sit alongside those filings and may help shape how investors think about that regulatory path, which remains the central catalyst for re rating the stock over the next year.

Yet, even as the data mature positively, investors still need to keep a close eye on the unresolved questions around regulatory comfort with external controls and long term safety...

Read the full narrative on uniQure (it's free!)

uniQure's narrative projects $445.8 million revenue and $20.0 million earnings by 2029.

Uncover how uniQure's forecasts yield a $62.42 fair value , a 171% upside to its current price.

Exploring Other Perspectives

Before this update, the most optimistic analysts were assuming revenue could reach about US$595.5 million and earnings US$165.6 million by 2029, which is far more bullish than consensus and could shift again as the new Huntington's data and regulatory feedback are digested.